Back to Search
Start Over
IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy.
- Source :
-
Cancer research communications [Cancer Res Commun] 2024 Aug 01; Vol. 4 (8), pp. 2045-2057. - Publication Year :
- 2024
-
Abstract
- Regulatory T cells (Treg) are highly enriched within many tumors and suppress immune responses to cancer. There is intense interest in reprogramming Tregs to contribute to antitumor immunity. OX40 and CD137 are expressed highly on Tregs, activated and memory T cells, and NK cells. In this study, using a novel bispecific antibody targeting mouse OX40 and CD137 (FS120m), we show that OX40/CD137 bispecific agonism induces potent antitumor immunity partially dependent upon IFNγ production by functionally reprogrammed Tregs. Treatment of tumor-bearing animals with OX40/CD137 bispecific agonists reprograms Tregs into both fragile Foxp3+ IFNγ+ Tregs with decreased suppressive function and lineage-instable Foxp3- IFNγ+ ex-Tregs. Treg fragility is partially driven by IFNγ signaling, whereas Treg instability is associated with reduced IL2 responsiveness upon treatment with OX40/CD137 bispecific agonists. Importantly, conditional deletion of Ifng in Foxp3+ Tregs and their progeny partially reverses the antitumor efficacy of OX40/CD137 bispecific agonist therapy, revealing that reprogramming of Tregs into IFNγ-producing cells contributes to the anti-tumor efficacy of OX40/CD137 bispecific agonists. These findings provide insights into mechanisms by which bispecific agonist therapies targeting costimulatory receptors highly expressed by Tregs potentiate antitumor immunity in mouse models.<br />Significance: The bispecific antibody FS120, an immunotherapy currently being tested in the clinic, partially functions by inducing anti-tumor activity of Tregs, which results in tumor rejection.<br /> (©2024 The Authors; Published by the American Association for Cancer Research.)
- Subjects :
- Animals
Mice
Mice, Inbred C57BL
Humans
Cell Line, Tumor
Female
T-Lymphocytes, Regulatory drug effects
T-Lymphocytes, Regulatory immunology
Receptors, OX40 agonists
Receptors, OX40 immunology
Tumor Necrosis Factor Receptor Superfamily, Member 9 agonists
Interferon-gamma metabolism
Antibodies, Bispecific pharmacology
Antibodies, Bispecific therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 2767-9764
- Volume :
- 4
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Cancer research communications
- Publication Type :
- Academic Journal
- Accession number :
- 38995700
- Full Text :
- https://doi.org/10.1158/2767-9764.CRC-23-0500